Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01465061
Other study ID # MED01032011
Secondary ID
Status Completed
Phase N/A
First received October 26, 2011
Last updated November 1, 2011
Start date February 2011
Est. completion date August 2011

Study information

Verified date November 2011
Source University of the Philippines
Contact n/a
Is FDA regulated No
Health authority Philippines: Ethics Committee
Study type Observational

Clinical Trial Summary

With the rise of usage of the internet, online social networks have recently been gaining popularity. Joining these groups can be beneficial to patients with chronic medical illness, such as psoriasis.This was a cross-sectional online survey of psoriasis patients in the Philippines who are members of online support groups. The survey was conducted for a period of three months.The purpose of the research project was to describe the demographics, disease characteristics, activities and benefits of online support groups to Filipino patients with psoriasis. The extent to which members experience empowering processes and outcomes was also evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date August 2011
Est. primary completion date June 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- diagnosis of psoriasis

- individuals who are willing to complete the online survey

- proficiency in English

- membership in an online psoriasis support network

Exclusion Criteria:

- nonmembers

- unwilling to participate in the study

Study Design

Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Intervention

Behavioral:
Online support group
Joining online support group

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of the Philippines Philippine Dermatological Society

Outcome

Type Measure Description Time frame Safety issue
Primary Demographic profile of online support users The sociodemographic profile of the respondents such as age (mean, range), sex, civil status, level of formal education, employment status were described. 3 months No
Primary Disease characteristics of online support users The overall health status (poor, average, good), psoriasis severity (mild, moderate, severe), duration of illness of online support groups were evaluated. 3 months No
Secondary Activities performed and extent of participation of online support users Participants were also asked regarding their attitudes and experiences with online communities, length of use, log-on frequency and nature of online activities. 3 months No
Secondary Empowering processes and outcomes experienced by online support group members The frequency with which empowering processes (exchange information, find recognition, share experiences, encounter emotional support, help others) occurred were measured on a 3-point scale (1-seldom to never, 2-sometimes, 3-often). The outcomes experienced (are better informed, feel more confident in relationship with physician, have improved acceptance, feel more confident with treatment, have enhanced social well-being, have increased optimism and control over the future, have enhanced self-esteem) were assessed on a 3-point scale (1-disagree, 2-neither agree nor disagree, 3-agree). 3 months No
Secondary Correlation of variables Intervariable correlation (overall health status/psoriasis severity with frequency/duration of usage, educational level/employment status with frequency of usage) were also be assessed for significance. 3 months No
See also
  Status Clinical Trial Phase
Completed NCT03236870 - A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
Completed NCT00078819 - Etanercept (Enbrel®) in Psoriasis - Pediatrics Phase 3
Completed NCT04841187 - Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
Active, not recruiting NCT03927352 - The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis Phase 3
Completed NCT03284879 - Post-Marketing Surveillance Study of OTEZLA
Recruiting NCT06027034 - Effectiveness of a Digital Health Application for Psoriasis N/A
Not yet recruiting NCT06050330 - CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study N/A
Recruiting NCT05744466 - A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Completed NCT04149587 - A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
Completed NCT01384630 - Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis Phase 2
Completed NCT03998683 - A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis Phase 3
Terminated NCT03556202 - A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06077331 - A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis Phase 2
Completed NCT04316585 - A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants Phase 1
Completed NCT04894890 - A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
Completed NCT00358384 - Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 Phase 1
Completed NCT03757013 - A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Completed NCT05003531 - A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Phase 2